Like many countries, Indonesia is still reeling from the effects of the COVID-19 pandemic. But the country has also gone through several other natural disasters at the same time. In one case, destructive landslides in the Majene region damaged property and injured three people with hemophilia (PWH). All three suffered bleeds because of the disaster, and were in need of factor. This factor—available to the Indonesian Hemophilia Society (HIS) thanks to donations provided by the WFH Humanitarian Aid Program—was readily available, but transporting it to the patients was challenging because of infrastructure damage. Fortunately, after exploring many options, the donated medicine was successfully delivered, along with the necessary injection equipment, so the three PWH would administer the factor themselves.
The WFH Humanitarian Aid Program has provided factor to Indonesia for many years, and donated over 2.4 million IUs to the country in 2020, and over 12 million IUs since 2015. To find out more about the Program and the difference it’s making in lives everywhere, click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.